World Library  
Flag as Inappropriate
Email this Article

Sch-58261

Article Id: WHEBN0014466160
Reproduction Date:

Title: Sch-58261  
Author: World Heritage Encyclopedia
Language: English
Subject: CGS-15943, 8-Chlorotheophylline, 8-Cyclopentyl-1,3-dimethylxanthine, Xanthine, Dimethazan
Collection: Adenosine Receptor Antagonists
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Sch-58261

SCH-58261
Systematic (IUPAC) name
5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
Clinical data
Legal status
  • Uncontrolled
Identifiers
CAS number  N
ATC code None
PubChem
IUPHAR ligand
ChemSpider  YesY
ChEMBL  YesY
Chemical data
Formula C18H15N7O 
Mol. mass 345.357 g/mol
 N   

SCH-58261 is a drug which acts as a potent and selective antagonist for the adenosine receptor A2A, with more than 50x selectivity for A2A over other adenosine receptors.[1] It has been used to investigate the mechanism of action of caffeine, which is a mixed A1 / A2A antagonist, and has shown that the A2A receptor is primarily responsible for the stimulant effects of caffeine, but blockade of both A1 and A2A receptors is required to accurately replicate caffeine's effects in animals.[2][3][4][5] SCH-58261 has also shown antidepressant[6] and neuroprotective effects in a variety of animal models,[7][8][9][10][11] and has been investigated as a possible treatment for Parkinson's disease.[12][13]

See also

References

  1. ^ Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S (February 1996). "The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist". The Journal of Pharmacology and Experimental Therapeutics 276 (2): 398–404.  
  2. ^ Svenningsson P, Nomikos GG, Ongini E, Fredholm BB (August 1997). "Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens". Neuroscience 79 (3): 753–64.  
  3. ^ Popoli P, Reggio R, Pèzzola A, Fuxe K, Ferré S (July 1998). "Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats". Neuroscience Letters 251 (3): 201–4.  
  4. ^ El Yacoubi M, Ledent C, Ménard JF, Parmentier M, Costentin J, Vaugeois JM (April 2000). "The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors".  
  5. ^ Kuzmin A, Johansson B, Gimenez L, Ogren SO, Fredholm BB (February 2006). "Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 16 (2): 129–36.  
  6. ^ El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology 61 (11 Suppl 6): S82–7.  
  7. ^ Monopoli A, Lozza G, Forlani A, Mattavelli A, Ongini E (December 1998). "Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats". NeuroReport 9 (17): 3955–9.  
  8. ^ Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pèzzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M (March 2002). "Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism,  
  9. ^ Melani A, Gianfriddo M, Vannucchi MG, Cipriani S, Baraldi PG, Giovannini MG, Pedata F (February 2006). "The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia". Brain Research. 1073-1074: 470–80.  
  10. ^ Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K, Popoli P (May 2007). "Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration". Journal of Neuropathology and Experimental Neurology 66 (5): 363–71.  
  11. ^ Canas PM, Porciúncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA (November 2009). "Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway". Journal of Neuroscience 29 (47): 14741–51.  
  12. ^ Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Schwarzschild MA (May 2001). "Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease". Journal of Neuroscience 21 (10): RC143.  
  13. ^ Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (October 2006). "Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease". Journal of the Neurological Sciences 248 (1-2): 48–52.  



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.